News
Nonetheless, Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in ...
Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...
Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...
Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication ...
AstraZeneca Readies for Tagrisso Competition in First-Line Advanced Lung Cancer as Q2 Revenues Surge
The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...
Troy Griffin discusses Gilead's mission to provide HIV education and resources at Chicago's Chosen Few Picnic, addressing community stigma.
Gilead To Supply Lenacapavir For People In Low- And Lower-middle-income Countries July 09, 2025 — 08:15 am EDT Written by RTTNews.com for RTTNews -> ...
Gilead Sciences, Inc. (NASDAQ: GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of Bernstein maintained a “Buy” rating on the company’s stock, retaining a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results